1O'Rielly DD, Rahman P. Genetics of psoriatic arthritis[J]. Best Pract Res Clin Rheumatol, 2014, 28(5): 673-685. DOI: 10. 1016/j.berh.2014.10.010.
2Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis[J]. Autoimmun Rev, 2014, 13(4/5): 496-502. DOI : 10.1016/j.autrev.2014.01.050.
3FitzGerald O, Haroon M, Giles JT, et al. Concepts of patho- genesis in psoriatic arthritis: genotype determines clinical pheno- type[J]. Arthritis Res Ther, 2015, 17(1): 115. DOI: 10.1186/ s 13075-015-0640-3.
4Sherlock JP, Taylor PC, Buekley CD, et al. Spondyloarthro- pathy: interleukin 23 and disease modification[J]. Lancet. 2015, 385(9982): 2017-2018. DOI: 10.1016/s01.40-6737(15)60970- 9.
5Popadic S, Ramic Z, Medenica LJ, et al. IL-23R gene poly- morphism rs2201841 is associated with psoriatic arthritis[J]. Int J Immunogenet, 2014, 41(4): 335-337. DOI: 10.1111/iji.121 27.
6Garg N, Truong B, Ku JH, et al. A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic[J]. Clin Rheumatol,2015, 34(10) : 1745-1751. DOI: 10.1007/s10067-014-2658-3.
7Silvy F, Bertin D, Bardin N. Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics[J]. PLoS One, 2015, 10(7): e0134218. DOI: 10.1371/journal.pone.013 4218.
8Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/ S100A9): a potential marker of inflammation in patients with psoriatic arthritis[J]. J Immunol Res, 2014, 2014: 696415. DOI: 10.1155/2014/696415.
9Nska JB, Michalak-Stoma A, Juszkiewicz-Borowiec M, et al. The assessment of selected bone and cartilage biomarkers in psoriatic patients from Poland[J]. Mediators Inflamm, 2015, 2015 : 194535. DOI: 10.1155/2015/194535.
10Acosta-Felquer ML, Ferreyra-Garrott L, Matin J, et al. Re- mission criteria and activity indices in psoriatic arthritis[J]. Clin Rheumatol, 2014, 33(9): 1323-1330. DOI: 10.1007/s1006 7-014-2626-y.
